RE-BVS – Piemonte Repository

Sfoglia per AUTORE
STILGENBAUER S
Collezione AOU Alessandria

Items : 4

Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18-65 years with mantle cell lymphoma (TRIANGLE): 4·5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network. in Lancet (London, England) / Lancet. 2026 May 16;407(10542):1953-1967. doi: 10.1016/S0140-6736(26)00362-4.

2026
AOU Alessandria

Herhaus P; Wirths S; Meerten TV; Heß G; Jachimowicz RD; Kerkhoff A; Stilgenbauer S; Jiang L; Leppä S; da Silva MG; Shpilberg O; Vergote VKJ; Trneny M; Riise J; Mey U; Hutchings M; Walewski J; Jerkeman M; Giné E; Doorduijn J; Dreyling M; Hoster E; Ladetto M; Tix T; Unterhalt M; Schmidt C; Klapper W; Pott C; Stefani PM; et alii...

Rituximab Maintenance Added to Ibrutinib-Containing Therapy in Younger, Untreated Patients With Mantle Cell Lymphoma: Results From the TRIANGLE Trial. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2026 Jul 14:JCO2600705. doi: 10.1200/JCO-26-00705.

2026
AOU Alessandria

Ladetto M; Gutmair K; Tavarozzi R; Pawlikowski A; Schomaker M; Doorduijn J; Giné E; Jerkeman M; Walewski J; Hutchings M; Mey U; Riise J; Trneny M; Vergote VKJ; Horowitz NA; Gomes da Silva M; Leppä S; Jiang L; Stilgenbauer S; Kerkhoff A; Jachimowicz RD; Heß G; van Meerten T; Wirths S; Herhaus P; Novak U; Dierlamm J; Hänel M; Hanoun C; et alii...

Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network. in Lancet (London, England) / Lancet. 2024 May 25;403(10441):2293-2306. doi: 10.1016/S0140-6736(24)00184-3. Epub 2024 May 2.

2024
AOU Alessandria

Dreyling M; Doorduijn J; Giné E; Jerkeman M; Walewski J; Hutchings M; Mey U; Riise J; Trneny M; Vergote V; Shpilberg O; Gomes da Silva M; Leppä S; Jiang L; Stilgenbauer S; Kerkhoff A; Jachimowicz RD; Celli M; Hess G; Arcaini L; Visco C; van Meerten T; Wirths S; Zinzani PL; Novak U; Herhaus P; Benedetti F; Sonnevi K; Hanoun C; et alii...

Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. in Leukemia / Leukemia. 2022 Jul;36(7):1870-1878. doi: 10.1038/s41375-022-01582-5. Epub 2022 May 13.

2022
AOU Alessandria
AOU Città della Salute di Torino

Deckert M; Ponzoni M; Pennese E; Cabras G; Thurner L; Smith J; Rummel M; Hertenstein B; Schmoll HJ; Krause SW; Zanni M; Pisani F; Orsucci L; Tucci A; Panse J; Stilgenbauer S; Hess G; Keller U; Balzarotti M; Pukrop T; Gørløv JS; Linton KM; Johnson PW; Hemmaway C; Roth A; Krampera M; Ilariucci F; Fabbri A; Binder M; et alii...